Sensei Biotherapeutics publishes a Nature Communications paper on SNS-101, a drug targeting VISTA in cancer immunotherapy.

Sensei Biotherapeutics announces the publication of a Nature Communications paper detailing the mechanism of action for SNS-101, a drug targeting the active form of VISTA within tumor microenvironments. The protein VISTA, previously considered undruggable, plays a significant role in suppressing T-cell activation. Collaborating with genOway and Dr. Robert Schreiber's lab, Sensei's drug aims to enhance cancer immunotherapy.